This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Daikoku, T. Articles by Dey, S. K. Search for Related Content PubMed PubMed Citation Articles by Daikoku, T. Articles by Dey, S. K.

Cyclooxygenase-1 Is Overexpressed in Multiple Genetically Engineered Mouse Models of Epithelial Ovarian Cancer

Departments of ¹ Pediatrics, ² Cell and Developmental Biology, and ³ Pharmacology, Division of Reproductive and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee; ⁴ Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; ⁵ Department of Biomedical Sciences, Cornell University, Ithaca, New York; and ⁶ Fox Chase Cancer Center, Philadelphia, Pennsylvania

Requests for reprints: Sudhansu K. Dey, Department of Pediatrics, Division of Reproductive and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN 37232. Phone: 615-322-8642; E-mail: sk.dey{at}vanderbilt.edu.

Cyclooxygenases-1 and -2 (Cox-1 and Cox-2) are two distinct isoforms that catalyze the conversion of arachidonic acid to prostaglandins. The role of Cox-2 in a variety of cancers is well recognized, but the contribution of Cox-1 remains much less explored. We have previously shown that human epithelial ovarian tumors have increased levels of Cox-1, but not Cox-2. We also observed that Cox-1 is highly expressed in a mouse model of epithelial ovarian cancer (EOC), which lacks p53 but overexpresses c-myc and K-ras or c-myc and Akt. More importantly, a Cox-1-selective inhibitor, SC-560, attenuates EOC growth. In the present investigation, we used various genetically engineered mouse models of EOC to determine whether Cox-1 overexpression is unique to specific genetic and oncogenic alterations or is widespread. These models include: (a) deletion of both p53 and Rb, (b) induction of the transforming region of SV40 under the control of Mullerian inhibitory substance type II receptor, or (c) activation of K-Ras in the absence of Pten locally in the ovarian surface epithelium. We found that these three models, which produce spontaneous EOC, also show up-regulated expression of Cox-1, but not Cox-2. The results provide further evidence that Cox-1 overexpression is common in various models of EOC. Thus, Cox-1 serves as a potential marker of EOC and is a possible target for the prevention and/or treatment of this deadly disease. (Cancer Res 2006; 66(5): 2527-31)

This article has been cited by other articles:

				T. Daikoku, Y. Hirota, S. Tranguch, A. R. Joshi, F. J. DeMayo, J. P. Lydon, L. H. Ellenson, and S. K. Dey Conditional Loss of Uterine Pten Unfailingly and Rapidly Induces Endometrial Cancer in Mice Cancer Res., July 15, 2008; 68(14): 5619 - 5627. [Abstract] [Full Text] [PDF]

				T. Daikoku, S. Tranguch, A. Chakrabarty, D. Wang, D. Khabele, S. Orsulic, J. D. Morrow, R. N. DuBois, and S. K. Dey Extracellular Signal-Regulated Kinase Is a Target of Cyclooxygenase-1-Peroxisome Proliferator-Activated Receptor-{delta} Signaling in Epithelial Ovarian Cancer Cancer Res., June 1, 2007; 67(11): 5285 - 5292. [Abstract] [Full Text] [PDF]

				W.-L. Yang, K. Q. Cai, J. L. Smedberg, E. R. Smith, A. Klein-Szanto, T. C. Hamilton, and X.-X. Xu A Reduction of Cyclooxygenase 2 Gene Dosage Counters the Ovarian Morphological Aging and Tumor Phenotype in Wv Mice Am. J. Pathol., April 1, 2007; 170(4): 1325 - 1336. [Abstract] [Full Text] [PDF]

				A. Y. Ting, B. F. Kimler, C. J. Fabian, and B. K. Petroff Characterization of a preclinical model of simultaneous breast and ovarian cancer progression Carcinogenesis, January 1, 2007; 28(1): 130 - 135. [Abstract] [Full Text] [PDF]